JP2006517973A - 新規な治療方法および局所投与用組成物 - Google Patents

新規な治療方法および局所投与用組成物 Download PDF

Info

Publication number
JP2006517973A
JP2006517973A JP2006503567A JP2006503567A JP2006517973A JP 2006517973 A JP2006517973 A JP 2006517973A JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006517973 A JP2006517973 A JP 2006517973A
Authority
JP
Japan
Prior art keywords
skin
nominal flux
photoaging
flux
drug substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517973A5 (https=
Inventor
デイビス，エイドリアン，フランシス
トロテット，ライオネル
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2006517973A publication Critical patent/JP2006517973A/ja
Publication of JP2006517973A5 publication Critical patent/JP2006517973A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006503567A 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物 Withdrawn JP2006517973A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Publications (2)

Publication Number Publication Date
JP2006517973A true JP2006517973A (ja) 2006-08-03
JP2006517973A5 JP2006517973A5 (https=) 2007-03-29

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503567A Withdrawn JP2006517973A (ja) 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物

Country Status (4)

Country Link
EP (1) EP1594959A4 (https=)
JP (1) JP2006517973A (https=)
GB (1) GB0303609D0 (https=)
WO (1) WO2004073622A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520166A (ja) * 2007-02-28 2010-06-10 ジュリアーニ インターナショナル リミテッド 免疫保護性刺激物質としてカチオン性抗菌ペプチド発現を誘導するためのＰＰＡＲ−γアゴニスト

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
WO2010091894A2 (en) 2009-02-16 2010-08-19 Giuliani International Limited Methods of treating hair related conditions
EP2515830A4 (en) * 2009-12-21 2014-06-04 B C Unlimited Liability Company COMPOSITIONS AND METHODS FOR INCREASING CELL GREASE AND SKIN LAUNDERING
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10722503B2 (en) 2017-02-22 2020-07-28 Jeffrey L. SUGARMAN Glitazones for topical application
EP4495101A3 (en) 2019-02-08 2025-04-30 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2002076177A2 (en) * 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520166A (ja) * 2007-02-28 2010-06-10 ジュリアーニ インターナショナル リミテッド 免疫保護性刺激物質としてカチオン性抗菌ペプチド発現を誘導するためのＰＰＡＲ−γアゴニスト

Also Published As

Publication number Publication date
WO2004073622A3 (en) 2005-01-20
EP1594959A4 (en) 2006-05-03
EP1594959A2 (en) 2005-11-16
GB0303609D0 (en) 2003-03-19
WO2004073622A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
JP2006517973A (ja) 新規な治療方法および局所投与用組成物
KR101715631B1 (ko) 피부 관리를 위한 조성물 및 방법
JP3921202B2 (ja) 抗刺激性酒さ治療
JP5570992B2 (ja) 皮膚病又は皮膚病変の治療方法及び組成物
US6437002B1 (en) Agent for preventing and treating skin diseases
CA3132958A1 (en) Topical compositions and methods for treating inflammatory skin diseases
KR20190101948A (ko) 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
BRPI0609630A2 (pt) composições e métodos para tratamento de doenças epidérmicas hiperproliferativas
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
JP2006524659A (ja) ケラチノサイトの過剰増殖、特に、アトピー性皮膚炎および乾癬を特徴とする疾患を治療するためのリルゾールの使用
US20060159648A1 (en) Novel therapeutic method and compositions for topical administration
JP5891651B2 (ja) 角層細胞分化正常化用皮膚外用剤
KR100274101B1 (ko) 9-시스 레틴산을 함유하는 약제학적 조성물
RU2152785C1 (ru) Применение антагониста cgrp для обработки лишаев и почесух (пруриго), композиция и способ обработки
JP2007525420A (ja) 新規な治療方法および局所投与用組成物
RU2630978C2 (ru) Фармацевтические составы для лечения заболеваний и состояний кожи, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидрохинолин
US20070086967A1 (en) Treatment of psoriasis with rosiglitazone
US20060142356A1 (en) Novel therapeutic method and compositions for topical administration
US20240180988A1 (en) Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores
JP2012506851A (ja) 局所脱色素用組成物及びその使用
JPH08109128A (ja) アレルギー性皮膚疾患治療用外用剤
KR102751617B1 (ko) 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
JP2021527634A (ja) Ｄｇａｔ１阻害剤の局所製剤およびそれらの使用の方法
AU2019208322A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
BR112020018138A2 (pt) Composições e métodos para tratar fibrose cutânea

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100730